Aerodynamic structures secured to the underbody of cargo bodies

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Stemco Lp patent solves the following problem:

Trucking is the primary means of long-distance and short-haul transportation of goods and materials in the United States, and in many other countries. Trucks often include a motorized cab where the driver sits and working on cars. cab attached to a box-like cargo section. Smaller trucks often include an integrated cargo section sitting in a unified framework which extends from the front wheels to the rear wheel assembly. The larger trucks often includes a detachable cab unit, with many driven axles, and a special trailer with a long box-like cargo units served on two or more phrases assemblies wheels. These trucks assemblages commonly called semi-trailers or tractor trailers. Most modern trucks' cabs, especially for tractor trailers, fitted with aerodynamic fairings on the roof, side and front. These fairings to help direct air over the exposed surface of the box-like cargo body, generally gave higher (a few feet) than the average roof cab. The flat, projecting front face of a cargo body is a strong source of drag on the cab roof. The use of the front-mounted aerodynamic fairings in recent years have served to significantly lower drag and, therefore, raise fuel economy for trucks, especially those traveling at high speed in the open roads.

Our analysis of this patent is as follows:

Stemco Lp’s patent US 9440689 B1 deals with Aerodynamic structures secured to the underbody of cargo bodies.
A flight underbody fairing or skirt that is attached to the rear wheels or bogeys in a cargo truck bodies generally can be slidably adjusted fore and aft along the cargo body. The various embodiments allow for a skirt that attaches bogeys in a cargo truck body and given back to the plane behind the trailer, and a retractable nature to allow for slidable change bogeys fore and aft along the cargo body for the purpose of continuing streamlined flow along the side of a cargo truck body equipped with a side of the border before the bogeys. In various embodiments of the invention, the retractable nature of the invention allows for a continuous edge surface of the plane with the side of the truck cargo bodies came from the back bogeys truck cargo plane body, without attention bogey position.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Dosage and formulation

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Almirall, S.A. patent solves the following problem:

Aclidinium bromide is 3 (R) – (2-hydroxy-2,2-dithien-2-ylacetoxy) -1- (3-phenoxypropyl) -1-azoniabicyclo [2.2.2] octane bromide, described in, for example WO 0104118. Although this compound is known as a long-acting anticholinergic useful in the treatment of respiratory diseases, the optimal dose was not disclosed.

Our analysis of this patent is as follows:

Almirall, S.A.’s patent US 9254262 B2 deals with Dosage and formulation.
The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder in a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Merck Sharp & Dohme Corp. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 9216173 B2 deals with 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors.
invention provides certain 2-pyridyl formamide-containing compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Fiber for synthetic grass field

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Tarkett Inc. patent solves the following problem:

Artificial grass fields (artificial turf) used for years to provide a surface that simulates natural grass. These artificial grass field there are many benefits to natural grass, and, moreover, can be installed and used in places that do not allow for natural grass fields.

Our analysis of this patent is as follows:

Tarkett Inc.’s patent US 9005723 B2 deals with Fiber for synthetic grass field.
A filament for use in an artificial grass field, where the filament has a front and a rear face and at least one of the front face and rear face includes a number of neighboring concave indentations gave general -from a first end to a second end.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Milk-based nutritional compositions containing lactoferrin and uses thereof

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Mead Johnson Nutrition Company patent solves the following problem:

Lactoferrin, an iron-binding glycoprotein, is one of the major multifunctional house agents in human milk. It has the capacity to bind to two molecules of iron in a consistent manner and facilitate the uptake of iron in the intestine. Moreover, lactoferrin has been shown that both bacteriostatic and bactericidal, and it helps to prevent intestinal infections in humans, especially in pediatric subjects.

Our analysis of this patent is as follows:

Mead Johnson Nutrition Company’s patent US 8968722 B2 deals with Milk-based nutritional compositions containing lactoferrin and uses thereof.
The present disclosure relates to milk-based nutritional composition comprising lactoferrin and / or a prebiotic component, which, when combined, lactoferrin and prebiotic component to show additive or synergistic beneficial effects on the health and development of a pediatric subjects. disclosure further relates to methods comprising the administration of the milk-based nutritional composition in pediatric subjects.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Use of nutritional compositions including lactoferrin and one or more prebiotics in inhibiting adhesion of pathogens in the gastrointestinal tract

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Mead Johnson Nutrition Company patent solves the following problem:

Disclosure This relates generally to the field of nutritional compositions, such as infant formulas, human milk fortifiers, children's dietary supplements, and the like, with lactoferrin, in particular lactoferrin produced in a non -tawhanong source. Particularly, the disclosure relates to a method of inhibiting the adhesion of at least one pathogen at a man in the gastrointestinal tract by administering human a nutritional composition including lactoferrin produced in a non-human source.

Our analysis of this patent is as follows:

Mead Johnson Nutrition Company’s patent US 8648036 B2 deals with Use of nutritional compositions including lactoferrin and one or more prebiotics in inhibiting adhesion of pathogens in the gastrointestinal tract.
A method for inhibiting the adhesion of at least one pathogen in the gastrointestinal tract of a man declared. In some embodiments, the method includes administering to a human in a nutritional composition including a fat or lipid source, a protein source, a prebiotic composition containing galactooligosaccharide and / or polydextrose and lactoferrin produced in a non-human source.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta -1,4/1,6 linkages

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The N.V. Nutricia patent solves the following problem:

Non-digestible oligosaccharides (NDO) is a major constituent of human milk. Human NDO promote the growth of beneficial microbiota dominated by bifidobacteria. The other known human NDO also be able to directly control the adhesion of pathogens and toxins. The presence of a microbiota rich in bifidobacteria associated with a reduced risk of atopic diseases such as atopic dermatitis, food allergies and asthma and a reduced risk of infection with these pathogens. Non-digestible oligosaccharides (NDO) therefore considered responsible for the lower incidence of infection and atopic disease observed in human milk fed infants when compared to infants fed formula. NDO is an important factor in the innate immune system in human milk, which the mother to protect the child, who had an experience and immature acquired immune system, and a not yet fully developed innate immune system .

Our analysis of this patent is as follows:

N.V. Nutricia’s patent US 8591919 B2 deals with Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta -1,4/1,6 linkages.
The present invention relates to a nutritional composition comprising at least two different beta-galacto-oligosaccharides (BGOS) A and B, where the majority of the linkages between the two galactose residues BGOS Usa beta 1.4 and / or beta 1.6, and most of the linkages between the two galactose residues BGOS B is the beta 1,3. Such mixtures show greater effects on the immune system and especially suitable for children's nutrition.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Appliance and a consumable holder in a network

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Whirlpool Corporation patent solves the following problem:

The invention relates to devices that hold consumables used or operated by a communication tool.

Our analysis of this patent is as follows:

Whirlpool Corporation’s patent US 8477007 B2 deals with Appliance and a consumable holder in a network.
A network includes a client and an appliance configured to perform an operation cycle of an article using a consumable. Information associated with the consumable be exchanged between the appliance and the client side of the network.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Human -adrenergic receptor kinase nucleic acid molecule

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Incyte Corporation patent solves the following problem:

Change protein phosphorylation is ubiquitous methods used to control many of intracellular events in eukaryotic cells. It is estimated that more than ten percent of the active protein in a typical mammal cell are phosphorylated. Kinases to facilitate the transfer of high-energy phosphate group from adenosine triphosphate (ATP) to the target protein hydroxyamino acid residues serine, threonine, or tyrosine. Phosphatases, in contrast, take the phosphate groups. Extracellular signal including hormone; neurotransmitter, growth and inequality factors may activate kinases, which takes place as the cell surface of cells or as activator in the final effector proteins, as well as other places along the way signal transduction. Cascade of kinases occur, as well as sensitive kinases second messenger molecules. This system allows for equipment to amplify the weak signal (lower abundance of growth factor molecules, for example), as well as the synthesis of many weak signal into an all-or-nothing answer. Phosphatases, then, is necessary to determine the extent of phosphorylation in cells and, with kinases, controlling key cellular processes such as metabolic enzyme activity, proliferation, cell growth and inequality, cell adhesion, and cell cycle progression.

Our analysis of this patent is as follows:

Incyte Corporation’s patent US 7829682 B1 deals with Human -adrenergic receptor kinase nucleic acid molecule.
Various embodiments of the invention provide human kinases and phosphatases (KPP) and polynucleotides which identify and encode KPP. Embodiments of the invention also giving expression vector, host cells, antibodies, agonists and antagonists. Some embodiments provide methods for diagnosing, treating, or preventing diseases associated with aberrant expression of KPP.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Phosphodiesterases

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Baughn Mariah R, , Lu Dyung Aina M, , Henry Yue, , Tang Y Tom, , Nguyen Danniel B patent solves the following problem:

Phosphodiesterases to create a class of enzymes that accelerate the hydrolysis of the two chains Ester with a phosphate compound. Phosphodiesterases therefore very important in a variety of cellular processes. Phosphodiesterases include DNA and RNA endonucleases and exonucleases, necessary for cell growth and reproduction, and topoisomerases, which break and after nucleic acid strands in the topological arrangement of the DNA. A Tyr-DNA phosphodiesterase functions in DNA repair by hydrolyzing dead-end covalent intermediates formed between topoisomerase I and DNA (Pouliot, JJ et al (1999) Science 286: 552-555; Yang, S.- W . (1996) Proc. …. Natl Acad Sci USA 93: 11534-11539).

Our analysis of this patent is as follows:

Baughn Mariah R, , Lu Dyung Aina M, , Henry Yue, , Tang Y Tom, , Nguyen Danniel B’s patent US 7122362 B2 deals with Phosphodiesterases.
human invention provides phosphodiesterases (HPDE) and polynucleotides which identify and encode HPDE. invention also provides expression vector, host cells, antibodies, agonists and antagonists. invention also provides methods for diagnosing, treating, or preventing diseases associated with aberrant expression of HPDE.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.